# Randomised controlled trial of oral versus intravenous therapy for clinically diagnosed acute uncomplicated diverticulitis

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
24/03/2008	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
11/04/2008	Completed	Results
Last Edited	Condition category	Individual participant data
11/04/2008	Digestive System	Record updated in last year

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Paul Ridgway

#### Contact details

Department of Surgical Oncology Room 3-130 Princess Margaret Hospital 610 University Ave Toronto Canada M5G 2M9

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

# Study information

#### Scientific Title

## Study objectives

Acute uncomplicated diverticulitis is a disease where outpouchings or blisters (termed Diverticulae) of the large bowel become inflamed resulting in pain and tenderness in the lower abdomen. Acute uncomplicated diverticulitis is currently treated with antibiotics although whether the antibiotics should be given through the veins or via the mouth is not known. Answering this question may allow treatment of the condition as an outpatient in the future.

Diverticulosis affects 5% of western society by the fifth decade, its prevalence increasing to over 50% in the ninth. As less than a quarter of acute admissions necessitate surgery, medical therapy remains the mainstay of management in the majority of cases. There are no prospective data to guide the identification of a specific cohort which may be managed with an oral antibiotic regimen, nor the efficacy of a specific antibiotic regimen.

The authors hypothesise that an oral antibiotic and fluid regimen is equally effective as intravenous antibiotics and 'bowel rest' in acute uncomplicated diverticulitis.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved by the Waterford Regional Ethics Board in 2002.

# Study design

Multi-centre randomised controlled trial.

## Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Not specified

# Study type(s)

**Treatment** 

## Participant information sheet

## Health condition(s) or problem(s) studied

Acute uncomplicated diverticulitis

## **Interventions**

Two intervention arms:

Intravenous arm: Intravenous ciprofloxacin (400 mg twice a day [BID]) and metranidazole (500

mg three times a day [TID]) with bowel rest for at least the first 24 hours. Oral arm: Oral ciprofloxacin (500 mg BID) and metranidazole (400 mg TID) without complete bowel rest.

Duration of the interventions was equivalent to the length of stay, with a maximal antibiotic duration decided by the attending physician, typically 7-10 days.

## Intervention Type

Drug

#### Phase

**Not Specified** 

# Drug/device/biological/vaccine name(s)

Ciprofloxacin and metranidazole

## Primary outcome measure

Resolution of symptoms. Three surrogates were used:

- 1. Resolution of left iliac fossa tenderness, assessed by the Wexford tenderness score (a locally validated score), daily assessment while an in-patient
- 2. Length of stay
- 3. Failure of oral therapy (requiring supplemental parenteral therapy). Follow-up: Until confirmatory/ refuting lower gastrointestinal (GI) series (endoscopic or contrast). Where such a test was not performed, follow-up to last out-patient appointment

## Secondary outcome measures

The following were evaluated as potential surrogates for resolution:

- 1. Serial erythrocyte sedimentation rate (ESR). Follow-up: Until confirmatory/ refuting lower GI series (endoscopic or contrast). Where such a test was not performed, follow-up to last outpatient appointment
- 2. C reactive protein (CRP). Follow-up: Until confirmatory/ refuting lower GI series (endoscopic or contrast). Where such a test was not performed, follow-up to last out-patient appointment
- 3. White cell count (WCC). Follow-up: Until confirmatory/ refuting lower GI series (endoscopic or contrast). Where such a test was not performed, follow-up to last out-patient appointment
- 4. Temperature charts, daily assessment while an in-patient

# Overall study start date

01/12/2002

# Completion date

31/05/2004

# **Eligibility**

## Key inclusion criteria

- 1. Patients presented with a clinical syndrome of left iliac fossa pain and local tenderness (Hinchey type I and II)
- 2. Both men and women

# Participant type(s)

#### **Patient**

## Age group

**Not Specified** 

#### Sex

Both

# Target number of participants

76

## Key exclusion criteria

- 1. Those with complicated Diverticulitis (Hinchey III and IV)
- 2. Those in Septic Shock
- 3. Allergies to antibiotics used in the trial
- 4. Hepatic or Renal insufficiency
- 5. Diagnosis is not clear
- 6. Co-morbid conditions necessitating prolonged hospital stay
- 7. Pregnant women or women who are breast feeding

## Date of first enrolment

01/12/2002

## Date of final enrolment

31/05/2004

# Locations

## Countries of recruitment

Canada

Ireland

# Study participating centre Department of Surgical Oncology

Toronto Canada M5G 2M9

# Sponsor information

## Organisation

Wexford General Hospital (Ireland)

## Sponsor details

Department of Surgery

\_

Ireland Wexford

# Sponsor type

Hospital/treatment centre

## **ROR**

https://ror.org/00bbdze26

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Wexford General Hospital, Department of Surgery (Ireland)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration